Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02446886 · ClinicalTrials.gov registry record · Phase 4
Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS
A Phase 4 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT02446886 is a Phase 4 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 15 participants.
The verdict
NCT02446886, a Phase 4 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine if monthly pulse doses of a three-day course ACTH (H.P. Acthar®) is more effective at recovering myelin at 12 months, as measured by myelin water fraction (MWF), in new multiple sclerosis lesions as compared to one course of treatment. The main secondary objective is to utilize every three month MWF measurements to determine the peak time of remyelination in new multiple sclerosis lesions when followed over the course of 12 months.
Interventions
- DRUG Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2016-06 |
| Est. Completion | 2020-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02446886
The ClinicalTrials.gov registry entry for NCT02446886 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®) is the first listed.
NCT02446886 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02446886 about?
NCT02446886 is a clinical study titled "Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS". The primary objective of this study is to determine if monthly pulse doses of a three-day course ACTH (H.P. Acthar®) is more effective at recovering myelin at 12 months, as measured by myelin water fraction (MWF), in new multiple sclerosis lesions as compared to one course of treatment. The main se...
What is the current status of trial NCT02446886?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2016-06. Estimated completion is 2020-06.
What interventions are being tested in trial NCT02446886?
The interventions under investigation include: Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®) (DRUG).
Who is sponsoring clinical trial NCT02446886?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.